CD274 and non-small cell lung carcinoma: Due to the results of the phase 3 trials, the supporting evidence from the FDA analysis, and excellent tolerability, single agent ICI is now widely accepted as a first-line systemic therapy option for patients with stage IV NSCLC non-squamous and squamous histology harboring a PD-L1 ≥ 50% with clinical trial median OS ranging from 20.2 to 26.3 months [7,9,10].